 Connection
Edwin deZoeten to Inflammatory Bowel Diseases
This is a "connection" page, showing publications Edwin deZoeten has written about Inflammatory Bowel Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.284 |
|
|
|
-
Hall CHT, de Zoeten EF. Understanding very early onset inflammatory bowel disease (VEOIBD) in relation to inborn errors of immunity. Immunol Rev. 2024 Mar; 322(1):329-338.
Score: 0.675
-
Constant BD, Dutmer CM, Arnold MA, Hall C, Abbott JK, de Zoeten EF. Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult-to-Treat Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 04; 20(4):e696-e702.
Score: 0.563
-
Denson LA, Curran M, McGovern DPB, Koltun WA, Duerr RH, Kim SC, Sartor RB, Sylvester FA, Abraham C, de Zoeten EF, Siegel CA, Burns RM, Dobes AM, Shtraizent N, Honig G, Heller CA, Hurtado-Lorenzo A, Cho JH. Challenges in IBD Research: Precision Medicine. Inflamm Bowel Dis. 2019 05 16; 25(Suppl 2):S31-S39.
Score: 0.491
-
Collins CB, Puthoor PR, Nguyen TT, Strassheim D, Jedlicka P, Friedman JE, de Zoeten EF. C/EBP? Deletion Promotes Expansion of Poorly Functional Intestinal Regulatory T Cells. J Crohns Colitis. 2018 Nov 28; 12(12):1475-1485.
Score: 0.475
-
MacManus CF, Collins CB, Nguyen TT, Alfano RW, Jedlicka P, de Zoeten EF. VEN-120, a Recombinant Human Lactoferrin, Promotes a Regulatory T Cell [Treg] Phenotype and Drives Resolution of Inflammation in Distinct Murine Models of Inflammatory Bowel Disease. J Crohns Colitis. 2017 Sep 01; 11(9):1101-1112.
Score: 0.436
-
Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE, Abraham C, Nusrat A, Jobin C, McCole DF, Siegel CA, Higgins PD, Herfarth HH, Hyams J, Sandborn WJ, Loftus EV, Kappelman MD, Lewis JD, Parkos CA, Sartor RB. Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):677-82.
Score: 0.319
-
de Zoeten E, Mamula P. What are the guidelines for using biologics in pediatric patients? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S259-61.
Score: 0.235
-
Constant BD, Albenberg L, Mitchel EB, De Zoeten EF, Clapp JT, Scott FI. Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey. Clin Gastroenterol Hepatol. 2024 02; 22(2):423-426.
Score: 0.163
-
McLaughlin L, DeZoeten E, Verneris MR. Can allogeneic haematopoietic cell transplantation be curative in classical Crohn's disease? Br J Haematol. 2023 03; 200(5):541-542.
Score: 0.156
-
Cheung T, de Zoeten EF, Hoffenberg EJ, Liu E, Pan Z, Walker T, Stahl M. Characteristics of Children With Inflammatory Bowel Disease and Coexisting Celiac Disease Seropositivity. J Pediatr Gastroenterol Nutr. 2022 12 01; 75(6):737-742.
Score: 0.155
-
Nicholson MR, Alexander E, Ballal S, Davidovics Z, Docktor M, Dole M, Gisser JM, Goyal A, Hourigan SK, Jensen MK, Kaplan JL, Kellermayer R, Kelsen JR, Kennedy MA, Khanna S, Knackstedt ED, Lentine J, Lewis JD, Michail S, Mitchell PD, Oliva-Hemker M, Patton T, Queliza K, Sidhu S, Solomon AB, Suskind DL, Weatherly M, Werlin S, de Zoeten EF, Kahn SA. Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease. J Crohns Colitis. 2022 06 24; 16(5):768-777.
Score: 0.152
-
Constant BD, de Zoeten EF, Stahl MG, Vajravelu RK, Lewis JD, Fennimore B, Gerich ME, Scott FI. Delays Related to Prior Authorization in Inflammatory Bowel Disease. Pediatrics. 2022 03 01; 149(3).
Score: 0.149
-
Sanctuary MR, Huang RH, Jones AA, Luck ME, Aherne CM, Jedlicka P, de Zoeten EF, Collins CB. miR-106a deficiency attenuates inflammation in murine IBD models. Mucosal Immunol. 2019 01; 12(1):200-211.
Score: 0.118
-
Hoffenberg EJ, McWilliams SK, Mikulich-Gilbertson SK, Murphy BV, Lagueux M, Robbins K, Hoffenberg AS, de Zoeten E, Hopfer CJ. Marijuana Use by Adolescents and Young Adults with Inflammatory Bowel Disease. J Pediatr. 2018 08; 199:99-105.
Score: 0.114
-
Furuta GT, Atkins D, Capocelli KE, de Zoeten EF, Fleischer D, Menard-Katcher C. Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease. J Pediatr Gastroenterol Nutr. 2013 Oct; 57(4):e25.
Score: 0.083
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|